Blogerroom logoBlogerroom
Medical
Medical

Health Canada Authorizes Moderna's mRNA Flu Shot for 50+

AS
Dr. Anand SharmaNovember 7, 20264 min read
Follow:FacebookยทPinterest
๐ŸŒ Language

Health Canada Authorizes Moderna's mRNA Flu Shot for 50+

Health Canada authorized Moderna's mRNA flu shot for adults 50+ on Nov. 5, with 26.6% relative efficacy over a standard shot and no launch date yet.

On Thursday, Nov. 5, Health Canada authorized two mRNA vaccines from Moderna for adults aged 50 and older: mFLUSIVA, a seasonal influenza vaccine, and mCOFLU, a combined influenza and COVID-19 vaccine. Moderna says Canada is the first country in the world to authorize both products, according to its announcement.

The authorization matters. The number attached to it matters more, and it is easy to misread.

What was authorized

Moderna said Health Canada's decision covers mFLUSIVA, also known as mRNA-1010, and mCOFLU, known as mRNA-1083, both for adults 50 and older. Moderna described mFLUSIVA as Canada's first mRNA seasonal flu vaccine and mCOFLU as the country's first combined flu and COVID-19 vaccine.

The claim of a world first applies to the pair. CBC News noted that the U.S. Food and Drug Administration has already approved mFLUSIVA for Americans 50 and older, so Canada is not the first regulator to clear the flu vaccine on its own. A Moderna spokesperson told CBC that Health Canada notified the company on Thursday.

Article image 1

What the trial showed

The authorization of mFLUSIVA rests on a Phase 3 trial of about 40,800 adults aged 50 and older across 11 countries, according to Moderna. The company reported a relative vaccine efficacy of 26.6% in adults 50 and older and 27.4% in adults 65 and older, compared with a standard-dose inactivated influenza vaccine.

Relative efficacy is not the same as how many flu cases the vaccine prevents. It means the mRNA vaccine produced about 27% fewer flu cases than the standard shot it was compared against, not that it prevents 27% of flu. Anyone reading the headline number as a stand-alone protection rate is misreading it.

There is a second catch for older adults. CBC reported that a higher-dose flu vaccine is recommended for people 65 and older because aging immune systems often need a bigger boost. The trial comparator was a standard-dose shot, so the reported figures do not show how mFLUSIVA performs against those higher-dose products, which are the usual choice for that age group.

The combination vaccine has thinner evidence

mCOFLU's authorization is supported by a Phase 3 trial of about 8,000 adults, according to Moderna. One financial news analysis noted that only mFLUSIVA has efficacy data of the kind reported above, while the combination product's authorization is supported by a smaller trial. A regulator's assessment of mCOFLU that separates what each trial measured was not available at the time of writing, so this is worth checking against Health Canada's own documents when they are published.

The obvious appeal of a combination vaccine is convenience: one injection instead of two.

Article image 2

What has not been decided

Moderna did not announce a launch date or a price. It said it will engage with Canadian health authorities and immunization partners on future availability of both vaccines. Authorization means Health Canada considers the products safe and effective for the stated use. It does not set out who should be offered the shot or who will pay for it.

For readers in Canada aged 50 or older, the practical step is to follow guidance from a health professional or provincial public health authority. Moderna has not said the vaccines will be available this winter.

Why this is worth watching

My read: the approval itself is less important than what Canada's public health advisers do with a vaccine that outperformed a standard flu shot in its trial but has not been measured against the high-dose version that older adults are usually offered. That comparison is the missing piece.

If it comes out in the mRNA vaccine's favour, it changes the flu-shot menu for the 65-and-over group. If it does not, the argument for mFLUSIVA becomes mostly about speed of manufacturing and convenience. Either way, Canada has just handed other regulators a second data point on an mRNA flu vaccine, and company-related reports say the vaccines are under review in other markets.

ShareWhatsAppTwitterLinkedIn
AS

Written by

Dr. Anand Sharma

Doctor and science communicator.

Enjoyed this? Follow us:FacebookPinterest
โ† Back to Medical